PLSE
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
Article Summary
HOLD- Pulse Biosciences Inc. (Nasdaq: PLSE) announced it will report business updates and financial results for the second quarter 2026 after market close on Thursday, August 6, 2026, with management hosting a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30 pm ET.
- Pulse Biosciences leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue as well as initiating regulated cell death, is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in select few other markets where it could have profound positive impact on healthcare for both patients and providers.
- Pulse is a novel bioelectric medicine company committed to health innovation that has the intention and potential to improve quality of life for patients.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | -6.1% | 25% | 0.0 ptsNegative (-6.1%) - Declining expectations |
| Target Price Upside ? | 1.4% | 20% | 20.0 ptsMinimal Upside (1.4%) - Target: $30.67 vs Current: $30.26 |
| Gross Margin % ? | -125.2% | 15% | 10.0 ptsRazor-Thin (-125.2%) - Weak pricing power |
| Drawdown from 52-Wk High ? | -2.4% | 15% | 20.0 ptsBarely a Dip (-2.4%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About PLSE
- Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
- It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians.
- The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
- Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.